16 November 2015 - According to the findings, an added clinical benefit is not proven in moderately emetogenic or in highly emetogenic chemotherapeutic regimens.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/netupitant/palonosetron-for-prevention-of-nausea-and-vomiting-added-benefit-not-proven.7056.html